Home > Gastroenterology > UEGW 2019 > Oncology > Ramosetron relieves low anterior resection syndrome

Ramosetron relieves low anterior resection syndrome

Prof. Kyu Joo Park, Seoul National University Hospital, Korea
UEGW 2019

Prof. Kyu Joo Park (Seoul National University Hospital, Korea) reported a randomised controlled trial to assess the effectiveness of ramosetron, a serotonin (5-hydroxytryptamine [5-HT]3) receptor antagonist, for the treatment of anterior resection syndrome. Ramosetron significantly improved both the Low Anterior Resection Syndrome (LARS) score, as well as quality of life [1].

5-HT3 receptor antagonists are effective for the treatment of irritable bowel syndrome, in which exaggerated intestinal/colonic hypermotility is observed. Recent studies have suggested that the motility disorder, especially spastic hypermotility, seen in the neorectum following sphincter-preserving operations for rectal cancer may be the basis of the post-operative defecatory malfunction seen in in 60-90% of patients, and for whom there are no effective treatments.

The investigators wished to in...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on